Pharmaceutical companies Eli Lilly and Co and Boehringer Ingelheim announced that their type 2 diabetes treatment, empagliflozin, has been shown to work in four late-stage trials.
According to a Reuters report, the companies expect to file for regulatory review of the drug in the United States, Europe and Japan in 2013, and will present detailed data from the trials.
Diabetes treatment is a potentially lucrative market, especially in light of recent health ...
continue reading...A report in Health Magazine says the type 2 diabetes drug Byetta could put patients at risk for kidney problems, including kidney failure.
According to the report, Byetta is a relatively new drug that’s proven popular because it can promote weight loss and it’s easier to inject than insulin.
But within two years of its approval in 2005, it was linked to a higher risk of acute pancreatitis, which is a potentially life-threatening inflammation of the pancreas that can lead to pancreatic ...
continue reading...According to U.S. Food and Drug Administration documents, the manufacturer of diabetes drug Byetta tried to conceal from federal regulators a study that linked the drug to potential heart problems.
In large part because of Amylin Pharmaceuticals’ deceitfulness, The Street reports, the FDA rejected another diabetes drug the company submitted for approval. And Amylin Pharmaceuticals subsequently misled investors about the reason for that rejection.
According to The Street, Amylin has been selling Byetta since 2005.
The drug has since generated some safety concerns. ...
continue reading...
The blog FiercePharma reports that the diabetes drug Victoza has performed well in a clinical study – performing better than competitors Januvia and Byetta in keeping patients’ blood sugar below a target of 7 percent.
Novo Nordisk, Victoza’s manufacturer, is working to secure more of an edge in what the blog entry describes as “the fast-growing diabetes market.” But it will likely face challenges in the form of a marketing blitz ...
continue reading...Poxel SA, a France-based company spun off from the pharmaceutical division of Merck, has raised $17.1 million in venture backing to fund a clinical trial for an experimental Type 2 diabetes drug, Bloomberg reports.
According to Bloomberg, the compound imeglimin is part of a new class of oral anti-diabetics called glimins, and has shown promising results in previous trials.
A safer alternative to existing medications could be a potentially lucrative market for ...
continue reading...A report on the blog FiercePharma says that a more stringent warning label for the diabetes drug Byetta spooked some investors when the U.S. Food and Drug Administration issued it in 2008.
At the time, Byetta manufacturers Eli Lilly and Amylin Pharmaceuticals had been in the process of developing a version of the drug that had to be administered only once a week, as opposed to the twice-daily version then on ...
continue reading...
